Molecular Templates, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
8-K: Molecular Templates Files for Chapter 11 Bankruptcy, Secures DIP Financing from K2 HealthVentures
Molecular Templates, Inc. and its affiliate have filed for Chapter 11 bankruptcy and entered into a restructuring support agreement with K2 HealthVentures, securing debtor-in-possession financing to continue operations.
Molecular Templates enters into a bridge loan agreement for immediate funding and amends its contingent value right agreement to address near-term financial obligations.
8-K: Molecular Templates Announces Mass Resignation of Board and Executive Team, Initiates Wind-Down
Molecular Templates has announced the resignation of its entire board and executive team, including the CEO, and has initiated a wind-down of its business affairs.
Molecular Templates, Inc. has received notice from Nasdaq that it is considered a public shell and will be delisted from the exchange.
Molecular Templates has cancelled its special stockholder meeting due to insufficient shareholder representation to achieve a quorum.
Molecular Templates' Chief Financial Officer, Jason Kim, has resigned, and CEO Eric Poma will serve as interim CFO.
Molecular Templates has received delisting notices from Nasdaq for failing to file its quarterly report and for its stock price falling below the minimum bid price, while also adjourning a special meeting to vote on the company's dissolution.
Molecular Templates plans to liquidate and wind up operations after failing to find viable strategic alternatives, pending stockholder approval.
Molecular Templates has announced a reduction in force of approximately 60% of its employees to extend resources while it continues to evaluate strategic alternatives.
Molecular Templates held its 2024 annual meeting, electing a new director, ratifying its auditor, and approving executive compensation on an advisory basis.
8-K: Molecular Templates Reports Positive Clinical Trial Data and Second Quarter 2024 Financial Results
Molecular Templates announced encouraging clinical trial results for its ETB platform and reported a reduced net loss for the second quarter of 2024 compared to the same period last year.
Molecular Templates reports positive interim clinical data for its MT-6402 and MT-0169 therapies, showing potential in treating solid tumors and immune-mediated diseases.
Molecular Templates announced its Q1 2024 financial results, showing a decrease in revenue and net income compared to the same period last year, but highlighted positive clinical trial data for its drug candidates.
Molecular Templates will reduce its workforce by approximately 30% to extend resources for its clinical studies, incurring an estimated $0.1 million in pre-tax charges.
8-K: Molecular Templates Reports Positive Clinical Data and Secures $9.5 Million in Private Placement
Molecular Templates announced positive clinical trial results for its cancer therapies and secured $9.5 million in a private placement to extend its cash runway.
Molecular Templates has finalized an amended agreement for a $9.5 million private placement, led by BVF Partners L.P., to fund ongoing clinical studies and general operations.
Molecular Templates and Bristol Myers Squibb will terminate their research collaboration agreement effective June 13, 2024, following BMS's decision to discontinue the partnership.
Molecular Templates reports the resignation of Jonathan Lanfear from the Board of Directors and the appointment of Kevin Lalande to the Audit Committee, effective January 11, 2024.